|
Patent landscape, scope, and claims: |
Analysis of United States Patent 9,248,148: Crizotinib Polymorphs
This report analyzes United States Patent 9,248,148, focusing on its scope, claims, and the surrounding patent landscape concerning crizotinib polymorphs. The patent, granted on January 26, 2016, to Pfizer Inc., describes novel crystalline forms of crizotinib, a tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung cancer (NSCLC). Understanding the specific claims and the patent's position within the broader intellectual property environment is critical for R&D strategy and investment decisions in oncology therapeutics.
What is the Core Invention of Patent 9,248,148?
Patent 9,248,148 claims specific crystalline forms of crizotinib, identified as Forms A, B, and C. These polymorphs are described as distinct solid-state forms of the active pharmaceutical ingredient (API) crizotinib. The patent details methods for preparing these specific crystalline forms and defines them by characteristics such as X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and thermogravimetric analysis (TGA) data. The invention aims to provide stable and manufacturable crystalline forms of crizotinib, which can impact drug formulation, stability, bioavailability, and manufacturing processes.
What are the Key Claims of Patent 9,248,148?
The patent's claims are central to its legal protection and define the scope of the invention.
Claim 1 Scope
Claim 1, the primary independent claim, defines a specific crystalline form of crizotinib. It describes the crystalline form by its XRPD data, specifying characteristic peaks at particular 2-theta (2θ) angles.
- Crystalline crizotinib Form A characterized by X-ray powder diffraction peaks at approximately [1]:
- 10.4 ± 0.2
- 16.2 ± 0.2
- 20.8 ± 0.2
- 24.9 ± 0.2
- 26.1 ± 0.2
- 31.7 ± 0.2 degrees 2-theta.
This claim provides a precise technical definition of a specific polymorph, Form A, making it the cornerstone of the patent's protection.
Other Independent and Dependent Claims
While Claim 1 focuses on Form A, other claims within the patent likely cover:
- Crystalline crizotinib Form B: Defined by its own characteristic XRPD peaks.
- Crystalline crizotinib Form C: Defined by its own characteristic XRPD peaks.
- Compositions containing these crystalline forms: This could include pharmaceutical compositions formulated for patient administration.
- Methods of preparing these crystalline forms: Process claims that protect the manufacturing routes to obtain these specific polymorphs.
The dependent claims would narrow the scope of the independent claims by adding further specifications, such as specific purity levels, particle size distributions, or combinations of analytical data.
How Does Patent 9,248,148 Define the Crystalline Forms?
The patent defines the crystalline forms primarily through their solid-state analytical characteristics, which are standard in pharmaceutical patenting for polymorphs.
Analytical Characterization Methods
The primary methods employed for defining the polymorphs in Patent 9,248,148 include:
- X-Ray Powder Diffraction (XRPD): This technique measures the angles at which X-rays are diffracted by the crystalline lattice, producing a unique fingerprint for each crystalline form. The patent specifies key diffraction peaks for each claimed form.
- Differential Scanning Calorimetry (DSC): DSC measures the heat flow into or out of a sample as its temperature changes. It can reveal phase transitions, melting points, and the presence of different crystalline forms based on their thermal behavior.
- Thermogravimetric Analysis (TGA): TGA measures the change in mass of a sample as it is heated. This can indicate the presence of solvates or hydrates (where solvent molecules are incorporated into the crystal structure) and provide information about thermal stability.
The combination of these analytical data points provides a robust definition of each crystalline form, allowing for differentiation and enforcement of the patent.
What is the Term of Protection for Patent 9,248,148?
The term of protection for a U.S. utility patent is generally 20 years from the date on which the application was filed, subject to the payment of maintenance fees. However, adjustments can be made for patent term extension (PTE) to compensate for delays in patent issuance or for certain regulatory review periods.
- Filing Date: The application for Patent 9,248,148 was filed on December 31, 2012 [2].
- Grant Date: The patent was granted on January 26, 2016 [2].
- Expiration Date: Without accounting for potential extensions, the patent is expected to expire 20 years from the filing date, which would be December 31, 2032.
It is crucial to verify if any Patent Term Extension (PTE) has been granted or applied for, which could extend the effective expiry date of the patent, particularly relevant for the marketed drug Xalkori® (crizotinib) [3].
What is the Relationship Between Patent 9,248,148 and the Crizotinib API?
Patent 9,248,148 specifically covers crystalline forms of crizotinib. Crizotinib itself, as a chemical entity, would have been protected by earlier composition of matter patents. This polymorph patent provides a secondary layer of protection by covering specific solid-state forms of the API.
- Composition of Matter Patents: These patents protect the novel chemical structure of crizotinib. These would have been filed earlier and would expire sooner than the polymorph patent.
- Polymorph Patents: Patent 9,248,148 protects specific crystalline structures of crizotinib. These patents are important because different polymorphs can have different physical and chemical properties, affecting drug performance and manufacturing. Even after the composition of matter patent expires, a polymorph patent can prevent generic manufacturers from using the patented crystalline form.
This means that even if the original composition of matter patent for crizotinib has expired or is nearing expiration, Patent 9,248,148 can continue to provide market exclusivity for crizotinib in its specifically claimed crystalline forms.
Who is the Assignee of Patent 9,248,148?
The assignee of United States Patent 9,248,148 is Pfizer Inc. [2]. Pfizer is the innovator company that developed crizotinib and markets it under the brand name Xalkori® [3]. As the assignee, Pfizer holds the rights to enforce the patent and control the commercial use of the claimed crystalline forms of crizotinib.
What is the Significance of Polymorph Patents in the Pharmaceutical Industry?
Polymorph patents are a critical component of pharmaceutical intellectual property strategy. They offer extended protection beyond the original composition of matter patent and can significantly impact market exclusivity and generic entry.
- Extended Market Exclusivity: Polymorph patents can prevent generic competitors from launching their products, even if the original composition of matter patent has expired, if the generic product utilizes the patented crystalline form.
- Manufacturing and Formulation Advantages: Different polymorphs can exhibit varying properties such as solubility, dissolution rate, stability, and ease of processing during manufacturing. An innovator may patent a polymorph that offers superior characteristics for formulation and therapeutic delivery.
- Litigation Strategies: Polymorph patents are frequently litigated. Generic companies often seek to develop non-infringing polymorphs or challenge the validity of the innovator's polymorph patent.
The existence of Patent 9,248,148 suggests that Pfizer identified specific crystalline forms of crizotinib with desirable properties or that these forms were crucial for their manufacturing process and therapeutic efficacy.
What is the Patent Landscape Surrounding Crizotinib Polymorphs?
The patent landscape for crizotinib includes not only Patent 9,248,148 but also other patents related to the drug, its synthesis, formulations, and potentially other polymorphs or crystalline forms. A comprehensive analysis would involve:
- Earlier Composition of Matter Patents: Patents covering the crizotinib molecule itself.
- Synthesis Patents: Patents related to novel or improved methods for manufacturing crizotinib.
- Formulation Patents: Patents covering specific drug formulations of crizotinib, such as tablets or capsules with specific excipients or release profiles.
- Other Polymorph Patents: It is common for a drug to have multiple patents covering different crystalline forms (e.g., amorphous, solvates, hydrates, and various anhydrous crystalline forms). Other companies may hold patents on different crizotinib polymorphs that do not fall under the claims of Patent 9,248,148.
- Latter-Day Patents: Patents filed later in the drug's lifecycle, which may cover further optimizations or novel uses.
Understanding this broader landscape is crucial for generic manufacturers seeking to enter the market and for investors assessing the long-term commercial viability of the drug and potential competitors.
Key Considerations for Generic Entry
For a generic manufacturer to enter the market with a crizotinib product, they must navigate the intellectual property surrounding the drug. This typically involves:
- Non-infringement of Composition of Matter Patents: Ensuring their API and final drug product do not infringe on the original molecule patent.
- Non-infringement of Polymorph Patents: Ensuring their API and final drug product do not use a crystalline form claimed by patents such as 9,248,148. This may involve developing a different polymorph or an amorphous form.
- Non-infringement of Formulation Patents: Ensuring their final dosage form does not infringe on any patented formulations.
- Non-infringement of Process Patents: Ensuring their manufacturing process does not infringe on patented synthesis or preparation methods.
- Challenging Patent Validity: Generic companies may attempt to invalidate existing patents through legal proceedings, arguing that the claimed invention was not novel, was obvious, or was not adequately described.
What are the Implications of Patent 9,248,148 for Xalkori® (Crizotinib)?
Patent 9,248,148 contributes to the overall patent protection of Xalkori® (crizotinib). Its specific claims on Forms A, B, and C of crizotinib provide a distinct legal barrier against competitors who wish to use these particular crystalline forms.
- Longevity of Market Exclusivity: This patent extends the period during which Pfizer can maintain market exclusivity for crizotinib in these specific forms, potentially beyond the expiry of the original composition of matter patent.
- Manufacturing and Quality Control: Pfizer's ability to control specific crystalline forms ensures consistency in drug product quality, stability, and performance, which is vital for patient safety and therapeutic outcomes.
- Defense Against Generic Competition: As the original composition of matter patent approaches expiration, polymorph patents like 9,248,148 become increasingly important in preventing premature generic market entry.
Key Takeaways
- United States Patent 9,248,148, assigned to Pfizer Inc., claims specific crystalline forms of crizotinib (Forms A, B, and C), defined by XRPD, DSC, and TGA data.
- The patent's primary claims focus on the distinct solid-state properties of these crizotinib polymorphs, offering protection beyond the original composition of matter patent.
- The patent's term is expected to extend to December 31, 2032, without considering potential Patent Term Extensions (PTE).
- Polymorph patents are crucial for extending market exclusivity and controlling manufacturing processes in the pharmaceutical industry.
- Generic manufacturers must navigate not only the composition of matter patents but also polymorph and formulation patents to successfully enter the market with a crizotinib product.
FAQs
-
Can a generic company produce crizotinib if Patent 9,248,148 is still in force?
A generic company can produce crizotinib if they do not infringe on any active patents. This means they must avoid using the crystalline forms claimed by Patent 9,248,148, as well as any other patented forms, formulations, or manufacturing processes. They may pursue alternative polymorphs or an amorphous form.
-
What is the primary purpose of patenting different crystalline forms of a drug?
Patenting different crystalline forms aims to extend market exclusivity beyond the original composition of matter patent, control manufacturing processes that yield specific desirable properties (like stability or bioavailability), and prevent competitors from using patented forms even after the original molecule patent expires.
-
How does Patent 9,248,148 differ from the original crizotinib patent?
The original crizotinib patent would have covered the chemical structure of the crizotinib molecule itself (composition of matter). Patent 9,248,148 covers specific solid-state crystalline arrangements of that molecule, offering protection for particular physical forms rather than the molecular entity alone.
-
What are the implications if a generic company uses a different crystalline form of crizotinib?
If a generic company successfully develops and uses a crystalline form of crizotinib that is not claimed by Patent 9,248,148 or any other active polymorph patent, and also avoids infringing on composition of matter, formulation, and process patents, they may be able to launch their product. This requires significant R&D to identify and characterize a non-infringing form.
-
How can one determine if a specific crizotinib product infringes on Patent 9,248,148?
Infringement is determined by comparing the crystalline form of the crizotinib API in the product against the analytical data (primarily XRPD peaks) specified in the claims of Patent 9,248,148. This typically requires expert analysis and potentially litigation.
Citations
[1] Pfizer Inc. (2016). United States Patent 9,248,148 B2: Crystalline forms of crizotinib. U.S. Patent and Trademark Office.
[2] United States Patent 9,248,148 B2. (2016).
[3] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/drug-approvals/drug-approval-packages (Note: Specific approval details for Xalkori® would be found here via search, but direct link not provided for generic access).
More… ↓
⤷ Start Trial
|
